SG Americas Securities LLC Takes $391,000 Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

SG Americas Securities LLC bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,804 shares of the specialty pharmaceutical company’s stock, valued at approximately $391,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Millennium Management LLC grew its stake in shares of Supernus Pharmaceuticals by 395.1% during the second quarter. Millennium Management LLC now owns 161,332 shares of the specialty pharmaceutical company’s stock valued at $4,316,000 after buying an additional 128,743 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Supernus Pharmaceuticals by 7.6% during the second quarter. The Manufacturers Life Insurance Company now owns 26,554 shares of the specialty pharmaceutical company’s stock valued at $710,000 after buying an additional 1,870 shares during the period. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at about $1,070,000. GAMMA Investing LLC increased its position in Supernus Pharmaceuticals by 97.1% during the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 398 shares during the period. Finally, Exchange Traded Concepts LLC bought a new stake in shares of Supernus Pharmaceuticals in the 3rd quarter valued at about $672,000.

Insider Activity at Supernus Pharmaceuticals

In related news, SVP Frank Mottola sold 15,000 shares of the company’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.98, for a total value of $554,700.00. Following the completion of the sale, the senior vice president now owns 8,200 shares in the company, valued at $303,236. This represents a 64.66 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 700 shares of the company’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the sale, the vice president now directly owns 10,149 shares of the company’s stock, valued at $402,103.38. The trade was a 6.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 154,913 shares of company stock valued at $5,687,914 over the last ninety days. Insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Stock Down 2.6 %

Shares of SUPN opened at $37.36 on Tuesday. The company has a market cap of $2.06 billion, a P/E ratio of 34.92 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $39.88. The firm’s 50 day moving average price is $37.16 and its 200 day moving average price is $34.59.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.25. The company had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. Supernus Pharmaceuticals’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.29) EPS. Research analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, Cantor Fitzgerald began coverage on shares of Supernus Pharmaceuticals in a research report on Monday, January 6th. They issued an “overweight” rating and a $57.00 target price for the company.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.